Abeona to initiate Phase I/II trial of ABO-102 in Australia to treat MPS IIIA

US-based biopharmaceutical company Abeona Therapeutics has secured regulatory approval from the Australian Health Therapeutic Goods Administration to commence a Phase I/II clinical trial of its ABO-102 for the treatment of Sanfilippo syndrome type A …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news